ArticleBMC pediatrics2026
Erdheim-Chester disease mimicking Wilms tumor in a child: a diagnostic challenge.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Pediatric Erdheim-Chester disease with cerebral ventricular system infiltration and epiphyseal involvement.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis driven by activating mutations of the MAPK signaling pathway, most commonly BRAF V600E. Pediatric cases are exceedingly rare and often present with atypical, multisystem manifestations, resulting in significant diagnostic delay. Renal and retroperitoneal involvement may mimic primary renal malignancies, particularly Wilms tumor. CASE PRESENTATION: We report a case of Erdheim–Chester disease in a child treated in Lviv, Ukraine. A male child who initially presented at two years of age with central diabetes insipidus and recurrent urinary tract infections. Over the following two years, the patient developed bilateral obstructive uropathy, retroperitoneal and paravertebral masses, and multifocal central nervous system and orbital involvement, raising concern for Wilms tumor. Recurrent urinary tract infections and progressive hydronephrosis necessitated multiple surgical interventions. Histopathological findings were initially non-specific. Due to clinicoradiologic–pathologic discordance, tissue-based molecular analysis was performed, which identified a pathogenic BRAF V600E mutation, confirming the diagnosis of Erdheim–Chester disease. Targeted therapy with the BRAF inhibitor dabrafenib was initiated, resulting in clinical and radiological stabilization.
conclusionsThis case highlights the diagnostic complexity of Erdheim–Chester disease in children and emphasizes the importance of considering histiocytic disorders in the differential diagnosis of renal and retroperitoneal masses. Multisystem involvement, atypical imaging findings, and molecular testing are key elements for accurate diagnosis and appropriate management, particularly in cases mimicking Wilms tumor, as misdiagnosis may lead to inappropriate surgical or chemotherapeutic interventions, delay targeted treatment, and adversely affect prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.